Phase III diabetes readout boosts Lexicon

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) jumped $2.54 (17%) to $17.85 on Friday after it said sotagliflozin ( SAR439954) met the primary endpoint in the Phase III Tandem1 study to treat Type I diabetes. Compared with placebo, the study's two doses of sotagliflozin each significantly reduced glycosylated HbA1c from baseline at 24 weeks (0.43% absolute reduction for the low dose, 0.49% for the high dose and 0.08% for placebo; p<0.001 for both doses).

The 793-patient trial studied 200 mg and 400 mg daily doses of the dual sodium-glucose cotransporter 1 ( SGLT1) and SGLT2 inhibitor in patients on a background of optimized insulin. Following a six-week optimization period, the mean baseline HbA1c level at randomization was 7.6% for all three dose arms. ...